The use of dendritic cell/tumor hybridomas as a novel tumor vaccine in patients with advance melanoma

Trial Profile

The use of dendritic cell/tumor hybridomas as a novel tumor vaccine in patients with advance melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Melanoma vaccine (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Mar 2017 Status changed to completed.
    • 19 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top